John Joseph

John Joseph


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2021 in Dermatologic Surgery
Verified
Journal Article
Open access
JKJoely Kaufman-Janette
Joely Kaufman-Janette
JJJohn Joseph
John Joseph
MKMichael S. Kaminer
Michael S. Kaminer
JCJames Clark
James Clark
SFSabrina G. Fabi
Sabrina G. Fabi
LBLawrence S. Bass
Lawrence S. Bass
BACKGROUND: Fibrous septae play a role in contour alterations associated with cellulite. OBJECTIVE: To assess collagenase clostridium histolyticum-aaes (CCH) for the treatment of cellulite. MATERIALS AND METHODS: Two identically designed phase 3, double-blind, randomized studies (RELEASE-1 and RELEASE-2) were conducted. Adult women with moderate/severe cellulite (rating 3–4 on the Patient Reported Photonumeric Cellulite Severity Scale [PR-PCSS] and Clinician Reported PCSS [CR-PCSS]) on the buttocks received up to 3 treatment sessions of subcutaneous CCH 0.84 mg or placebo per treatment area. Composite response (≥2-level or ≥1-level improvement from baseline in both PR-PCSS and CR-PCSS) was determined at Day 71. RESULTS: Eight hundred forty-three women received ≥1 injection (CCH vs placebo: RELEASE-1, n = 210 vs n = 213; RELEASE-2, n = 214 vs n = 206). Greater percentages of CCH-treated women were ≥2-level composite responders versus placebo in RELEASE-1 (7.6% vs 1.9%; p = .006) and RELEASE-2 (5.6% vs 0.5%; p = .002) and ≥1-level composite responders in RELEASE-1 (37.1% vs 17.8%; p < .001) and RELEASE-2 (41.6% vs 11.2%; p < .001). Most adverse events (AEs) in the CCH group were injection site related; few CCH-treated women discontinued because of an AE (≤4.3%). CONCLUSION: Collagenase clostridium histolyticum-aaes significantly improved cellulite appearance and was generally well tolerated.

16 July 2021 in Toxins
Verified
Journal Article
Open access
PDF file
JKjoely kaufman
joely kaufman
SCSue Ellen Cox
Sue Ellen Cox
SDSteven Dayan
Steven Dayan
JJJohn Joseph
John Joseph
Botulinum toxin serotype-A (BoNT-A) preparations are widely used to improve the appearance of wrinkles. While effective and well tolerated, patients require retreatment over time to re-establish the effects. There is growing interest from patients as to whether higher doses can prolong response without significantly increasing side effects. We reviewed the efficacy and safety evidence for high-dose BoNT-A treatment of glabellar lines, by evaluating high-dose studies published since 2015. Toxins approved for glabellar line treatment in the US or Europe were considered. “High-dose” indicated doses above the licensed dose for each BoNT-A preparation. Five studies met the inclusion criteria and most were randomized, double-blind trials; designs and population sizes varied. Findings suggested that higher-dose BoNT-A treatment is feasible and may improve response duration without increased safety issues. Around 9 months’ median duration was achieved with a 2–2.5-fold increase of the abobotulinumtoxinA on-label dose, or with a 5-fold increase in incobotulinumtoxinA dose. A 2–4-fold increase of the onabotulinumtoxinA on-label dose yielded a median duration of around 6 months. Importantly, patient satisfaction and natural look remained with increasing abobotulinumtoxinA doses. While more data are needed, these findings may lead to more effective, individually tailored treatment plans to meet patient expectations.

30 September 2021 in Dermatologic Surgery
Verified
Journal Article
Open access
HSHema Md Sundaram
Hema Md Sundaram
ASAva Shamban
Ava Shamban
JSJoel Schlessinger
Joel Schlessinger
JKjoely kaufman
joely kaufman
JJJohn Joseph
John Joseph
LELaura Eaton-Jankov
Laura Eaton-Jankov
BACKGROUND: The perioral region is highly mobile and subject to multifactorial changes during aging. Resilient Hyaluronic Acid Redensity (RHAR), an RHA filler, was developed with the aim of optimizing outcomes in dynamic facial areas. OBJECTIVE: This randomized, blinded, multicenter clinical study aimed to demonstrate superiority of RHAR over no-treatment control for correction of moderate-to-severe dynamic perioral rhytides. MATERIALS AND METHODS: Blinded live evaluator assessments of efficacy included improvement in perioral rhytides severity using a proprietary scale (Perioral Rhytids Severity Rating Scale [PR-SRS]) and the Global Aesthetic Improvement Scale. Subjects self-assessed their results with FACE-Q, a validated patient-reported outcome measure, and satisfaction scales. Safety was monitored throughout the study based on common treatment responses (CTRs) and adverse events (AEs). RESULTS: The primary efficacy end point was achieved, with the treatment group showing statistically significant superiority over the control group at Week 8 (80.7% vs 7.8% responder rate by PR-SRS, p < .0001). Most patients (66%) were still responders at Week 52 (study completion). Most AEs were CTRs after perioral injection of a dermal filler, and none was a clinically significant treatment-related AE. CONCLUSION: Resilient Hyaluronic Acid Redensity is effective and safe for the correction of dynamic perioral rhytides in all Fitzpatrick phototypes, with marked durability.

20 January 2022 in Journal of Cosmetic Dermatology
Verified
Journal Article
Open access
PDF file
PTPatrick Trevidic
Patrick Trevidic
WCWayne Carey
Wayne Carey
ABAnthony V. Benedetto
Anthony V. Benedetto
JJJohn Joseph
John Joseph
LELaura Eaton
Laura Eaton
PMPauline Maffert
Pauline Maffert
Background: Validated, objective clinical scales are needed to assess aesthetic improvement of the lips after augmentation with dermal fillers.Objective: To develop a lip fullness rating scale and establish its reliability for grading subjects in clinical trials or routine practice, and sensitivity for detecting clinically meaningful changes.Methods: The Teoxane Lip Fullness Scale (TLFS), a proprietary, 5‐grade photonumeric scale, was developed by clinical experts based on real subject photographs and was validated through both photographic and live subjects' evaluation.Results: Clinician intra‐ and inter‐rater agreement for the TLFS was substantial to almost perfect. Mean intra‐rater weighted Kappa score between the two rounds of photographic validation was 0.92, and inter‐rater agreement was substantial with an ICC of 0.93 for the combined rounds. Average intra‐rater weighted Kappa score and inter‐rater ICC for the live validation were equally high, reaching 0.91 and 0.89 respectively. Additionally, evaluators identified clinically significant differences between photographs of subjects presenting a 1‐grade or 2‐grade difference on the scale in 90% and 98% of cases, respectively.Conclusions: The intra‐rater Kappa scores and inter‐rater ICC met their pre‐determined acceptance criteria of >0.70 in the photographic and live validation. The TLFS was shown to be a repeatable and reproducible Clinician Reported Outcome (Clin‐RO) for healthcare providers to classify lip fullness both in clinical trials and in routine patient care. A 1‐grade difference on the TLFS can detect a clinically meaningful difference in lip fullness.

30 October 2024 in Aesthetic Surgery Journal
Verified
Journal Article
Open access
PDF file
JJJohn Joseph
John Joseph
VSVladimir Sudimac
Vladimir Sudimac
SMSabine Mersmann
Sabine Mersmann
MKMartina Kerscher
Martina Kerscher
Background: Two randomized, double-blind, placebo-controlled, Phase III studies of incobotulinumtoxinA for treating upper facial lines (UFLs; ie, a combination of glabellar frown lines [GFLs], horizontal forehead lines [HFLs], and lateral canthal lines [LCLs]) were conducted in the United States (ULTRA I: NCT04594213) and Germany (ULTRA II: NCT04622254). Objectives: The aim of this study was to evaluate the safety and efficacy of simultaneous intramuscular injections for UFLs. Longer-term safety and efficacy were assessed in open-label extension periods. Methods: Healthy participants (≥18 years) with moderate-to-severe GFLs, HFLs, and symmetric LCLs at maximum contraction on the 5-point Merz Aesthetics Scales were randomized 2:1:1 to receive up to 64 units of incobotulinumtoxinA in the main period for each trial. Treatment groups were: UFLs, GFLs, and HFLs (ULTRA I), LCLs (ULTRA II), and placebo. Primary efficacy endpoints were the proportions of GFL, HFL, and LCL responders, defined as a Merz Aesthetics Scale score for the respective area of 0 (no) or 1 (mild) and a ≥2-grade improvement from baseline to Day 30, as assessed by both investigator and participant. Results: Overall, 362 and 368 participants received treatment in ULTRA I and ULTRA II, respectively. In both studies, incobotulinumtoxinA treatment was significantly more effective than placebo with respect to the primary endpoints (P < .0001) and key secondary endpoints (P < .0001). The open-label extension period results were consistent with those seen in the main period. No new safety findings were identified. Conclusions: In ULTRA I and ULTRA II, the safety and efficacy of incobotulinumtoxinA for the simultaneous treatment of moderate-to-severe UFLs were demonstrated, with significant improvements across all primary and secondary endpoints vs placebo. Level of Evidence: 1 (Therapeutic):

1 November 2015 in Facial Plastic Surgery Clinics of North America
Verified
Journal Article
Closed access
JJJohn Joseph
John Joseph